Tuesday, 17 November 2026Peptide medicines at the counter: price, coverage, supply, rules.

Reading as
What is this?
PriceUS

Wegovy pill sales outrun the injection as a 2027 list price cut nears

Novo's Wegovy pill brought in DKK 5.39 billion in the third quarter, up 53 percent, while US injection sales fell 13 percent. The US list price of Wegovy and Ozempic drops to $675 a month on January 1, and what patients pay still depends on their plan.

Editorial illustration for the story: Wegovy pill sales outrun the injection as a 2027 list price cut nears
Illustration: Peptide Town. Cut-paper collage, not data.

Who feels it

  • Patients Adjust

    The US list price of Wegovy and Ozempic is set to fall to $675 a month on January 1, but your cost still depends on your plan or cash program.

  • Payers Adjust

    Novo describes Wegovy price erosion of 30 to 35 percent in the quarter, before the January list price cut takes effect.

  • Prescribers Worth knowing

    Novo says the pill captures around 80 percent of new to brand prescriptions as it outpaces Lilly's rival pill, so more starts are oral.

  • Pharmacies Worth knowing

    Expect a list price change on Wegovy and Ozempic claims from January 1 and more pill volume, while injection sales are shrinking.

  • Sellers Worth knowing

    Novo says pill volume runs through cash pay and telehealth channels as well as insured ones, so branded supply competes in those channels.

Novo Nordisk's Wegovy pill sales rose 53 percent from the second quarter to the third, reaching DKK 5.39 billion, or about $810 million, the company reported on November 4. Wegovy pill sales now more than make up for a shrinking US injection business. The timing matters for anyone who pays for the drug: on January 1, 2027, the US list price of Wegovy and Ozempic is set to drop to $675 a month. Novo has not said what it expects for 2027 sales, and its outlook for next year is due in February.

Novo Nordisk third quarter in numbers

The Novo Nordisk third quarter report shows growth returning after a weak stretch. Group adjusted sales reached DKK 79.2 billion, up 4 percent at constant exchange rates, and adjusted operating profit came to DKK 31.72 billion, up 27 percent on the same basis. Novo credited higher GLP 1 volumes, above all in obesity. It also raised its full year 2026 outlook for the third time this year. Adjusted sales and operating profit are now each expected to land between a 2 percent fall and a 2 percent rise at constant exchange rates, against a previous range of a 6 percent fall to flat. That band still allows a decline, so it reads as a cautious upgrade rather than a promise of growth.

Inside the US, the split between pill and injection is sharp. Sales of injectable Wegovy fell 13 percent at constant exchange rates in the quarter, while the whole US Wegovy business, pill included, grew 21 percent. On the earnings call, Novo said the pill was capturing around 80 percent of new to brand prescriptions in the US as it kept outpacing its oral rival, counting insured, cash pay and telehealth channels. Executives also put cumulative US pill prescriptions above 8 million since the January launch. For comparison, Eli Lilly's rival obesity pill Foundayo, launched in April, brought in $184 million in the quarter, below analyst estimates, BioPharma Dive reported. Lilly's pill started later, so the gap is not yet a like for like test.

MeasureThird quarter 2026Basis
Wegovy pill revenueDKK 5.39 billionUp 53% on the second quarter
US injectable WegovyDown 13%Constant exchange rates
US Wegovy pill and injection combinedUp 21%Constant exchange rates
Group adjusted salesDKK 79.2 billionUp 4% at constant rates
Adjusted operating profitDKK 31.72 billionUp 27% at constant rates
Full year 2026 outlookMinus 2% to plus 2%Was minus 6% to flat
US list price of Wegovy and Ozempic$675 a monthFrom January 1 2027

Wegovy list price cut in January

The second number readers should watch is the Wegovy list price cut. From January 1, 2027, the US monthly list price for both Wegovy and Ozempic is set at $675, according to an investor analysis published Thursday. That is roughly half the current list price of Wegovy and about 35 percent below that of Ozempic. Novo has said the change will weigh on cash flow next year, and it has given no growth commitment for 2027. The analysis does not say whether the pill gets a new list price on the same date, and we could not confirm one. A list price is the starting point that insurers, pharmacy benefit managers and cash programs negotiate from, not what most patients hand over at the counter.

A list price is the starting point that insurers, pharmacy benefit managers and cash programs negotiate from, not what most patients hand over at the counter.

For patients, the effect depends on how they pay. People with insurance usually owe a copay or coinsurance set by their plan. Where a patient owes a share of the drug's price, for example while meeting a deductible, a lower list price may trim that bill. People who pay cash already use Novo's self pay prices, which sit below list. Our guide to one pen and four prices explains why those numbers rarely match. On the payer side, Jyske Bank pointed to a tailwind from the Medicare GLP 1 Bridge, while Citi kept a neutral rating and cited limited visibility on pricing for 2027 and beyond. Both brokers are forecasting, and their views say nothing certain about what anyone will pay.

Wegovy injection sales and price erosion

The injection tells a different story from the pill. On the call, Novo said US volumes of injectable Wegovy grew about 10 percent from the second quarter, while pill volumes grew about 20 percent. Even so, Wegovy injection sales in the US were 13 percent lower in the quarter, the company reported. Executives described Wegovy price erosion of about 30 to 35 percent in the quarter, at the high end of their range, and said they expect that level or slightly better from here. Put simply, more packs are moving, but each one earns Novo less. That pattern started before the January list price change, a sign that deals with payers and cash channels were already pulling net prices down.

Novo is not alone in this squeeze. Our report on Lilly's quarter found the same pattern, with volume up sharply while realized prices fell. For payers, lower net prices could ease the cost of covering obesity drugs, although some large employers are still dropping weight loss coverage for 2027. Jyske listed pricing pressure, stronger competition and the semaglutide patent expiry among the risks for Novo. Citi expects tougher competition from 2028, naming Lilly's retatrutide, which is still an experimental drug, and it trimmed its longer term estimates by as much as 6 percent. Several brokers reportedly kept hold ratings after the results, so the raised forecast did not turn into warmer advice on the stock.

Wegovy pill rollout outside the US

The Wegovy pill rollout is also widening access abroad. The tablet is already sold in eight markets, and Novo plans to offer it in more than 20 countries by mid 2027, according to the analysis and other reports on the results. Of the DKK 5.39 billion in Wegovy pill sales, about DKK 1.22 billion came from outside the US, Quartz reported, citing The Wall Street Journal. Novo said on the call that the pill holds around 90 percent of the oral obesity segment in the UK. Each new market brings its own rules on price and public funding, and a launch does not mean a health system will pay. In several markets, obesity drugs are still paid for in cash.

Two dates close out the year. The FDA is expected to decide on CagriSema, Novo's next obesity candidate, by the end of 2026, and the company has said it is preparing a US launch in early 2027 if the drug is approved. Novo will also present 26 abstracts at ObesityWeek in Washington from November 14 to 17. Neither event changes what a patient pays today. The February outlook should be the first time Novo puts a number on how pill growth, lower list prices and its product mix add up for 2027. For the price change itself and how it reaches each kind of plan, our earlier story on the January cut has the details.

Conclusion

Wegovy pill sales gave Novo a stronger quarter and a higher 2026 forecast, but the money question for 2027 is still open. The US list price of Wegovy and Ozempic is set to fall to $675 a month on January 1, while net prices on the injection were already eroding. What patients pay will still depend on their plan, cash program or public coverage. Novo's February outlook is the next fact to watch. This story is for research and information only and is not medical advice.

Source Novo Nordisk third quarter 2026 report (company announcement 65/2026) and earnings call, 4 November 2026; ad-hoc-news.de investor analysis, 5 November 2026

Spotted an error? Tell us through the contact form; we follow the corrections policy.